Literature DB >> 16766198

Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.

Haibing Jiang1, Michelle A Poirier, Yideng Liang, Zhong Pei, Charlotte E Weiskittel, Wanli W Smith, Donald B DeFranco, Christopher A Ross.   

Abstract

Huntington's disease is a neurodegenerative disease caused by an expanded polyglutamine stretch within the huntingtin protein. Transfection of mutant huntingtin causes cell toxicity and depletion of CREB binding protein (CBP) or its recruitment into huntingtin aggregates. However, the role of CBP has been controversial and the relationship between polyglutamine-induced toxicity and CBP depletion has not been examined on an individual cell basis. Using a single-cell based assay, we found that, in HT22 cells or primary neurons transfected with mutant huntingtin, cell toxicity was accompanied by CBP depletion, rather than merely recruitment. Transfection with a htt exon1 construct containing uninterrupted polyglutamine or a polyglutamine region engineered to form a compact beta structure resulted in cell toxicity. CBP depletion was accompanied by histone hypo-acetylation. CBP overexpression rescued both acetylated histone levels and cell toxicity. These data suggest that CBP dysfunction and altered gene transcription contribute to mutant htt-induced neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766198     DOI: 10.1016/j.nbd.2006.04.011

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  52 in total

1.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

Review 2.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 3.  Acetyltransferases (HATs) as targets for neurological therapeutics.

Authors:  Anne Schneider; Snehajyoti Chatterjee; Olivier Bousiges; B Ruthrotha Selvi; Amrutha Swaminathan; Raphaelle Cassel; Frédéric Blanc; Tapas K Kundu; Anne-Laurence Boutillier
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 4.  Epigenetic mechanisms in stroke and epilepsy.

Authors:  Jee-Yeon Hwang; Kelly A Aromolaran; R Suzanne Zukin
Journal:  Neuropsychopharmacology       Date:  2012-08-15       Impact factor: 7.853

5.  CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.

Authors:  Yun-Sik Choi; Boyoung Lee; Hee-Yeon Cho; Iza B Reyes; Xin-An Pu; Takaomi C Saido; Kari R Hoyt; Karl Obrietan
Journal:  Neurobiol Dis       Date:  2009-07-24       Impact factor: 5.996

6.  Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment.

Authors:  Shona Mookerjee; Theodora Papanikolaou; Stephan J Guyenet; Vanitha Sampath; Amy Lin; Cathy Vitelli; Francesco DeGiacomo; Bryce L Sopher; Sylvia F Chen; Albert R La Spada; Lisa M Ellerby
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

7.  A large scale Huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease.

Authors:  Cendrine Tourette; Biao Li; Russell Bell; Shannon O'Hare; Linda S Kaltenbach; Sean D Mooney; Robert E Hughes
Journal:  J Biol Chem       Date:  2014-01-09       Impact factor: 5.157

8.  Pcaf modulates polyglutamine pathology in a Drosophila model of Huntington's disease.

Authors:  Laszlo Bodai; Judit Pallos; Leslie Michels Thompson; J Lawrence Marsh
Journal:  Neurodegener Dis       Date:  2011-09-10       Impact factor: 2.977

Review 9.  Defining the limits: Protein aggregation and toxicity in vivo.

Authors:  William M Holmes; Courtney L Klaips; Tricia R Serio
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-04-28       Impact factor: 8.250

Review 10.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.